Therapeutic vaccination for chronic diseases: A new class of drugs in sight

Nature Reviews Drug Discovery

Volumn 3, Issue 1, 2004, Pages 81-88

  Bachmann, Martin F ^a   Dyer, Mark R ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADJUVANT; ALZHEIMER DISEASE VACCINE; ANGIOTENSIN I; ANGIOTENSIN II ANTIBODY; CHOLERA TOXIN B SUBUNIT; CHOLESTEROL ESTER TRANSFER PROTEIN; COCAINE; ETANERCEPT; FREUND ADJUVANT; GASTRIN 17; GONADORELIN ANTAGONIST; INFLIXIMAB; INTERLEUKIN 5 ANTIBODY; INTERLEUKIN 9; KEYHOLE LIMPET HEMOCYANIN; METHOTREXATE; MONOCLONAL ANTIBODY; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEW DRUG; NICOTINE; PHOSPHORYL LIPID A; PSEUDOMONAS VACCINE; QS 21; RECOMBINANT CHORIONIC GONADOTROPIN; TETANUS TOXOID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG; VIRUS PROTEIN;

ACTIVE IMMUNIZATION; ALZHEIMER DISEASE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ASEPTIC MENINGITIS; CHRONIC DISEASE; CLINICAL TRIAL; COCAINE DEPENDENCE; CROHN DISEASE; CYTOLYSIS; DIAGNOSTIC TEST; DRUG APPROVAL; DRUG CLASSIFICATION; DRUG COST; DRUG EFFICACY; DRUG MARKETING; DRUG RESEARCH; DRUG SYNTHESIS; HEALTH CARE COST; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOPATHOGENESIS; INFECTION PREVENTION; MENINGOENCEPHALITIS; MOUSE; NONHUMAN; PATIENT ATTITUDE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PSORIASIS; RECEPTOR BLOCKING; RHEUMATOID ARTHRITIS; TOBACCO DEPENDENCE;

EID: 0347135823     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd1284     Document Type: Article

References (57)

1. Jennings, G. T. & Bachmann, M. F. Immunotherapies: cause for measured optimism. Drug Discov. Today 7, 994-946 (2002).
2. WHO. Population ageing - a public health challenge [online],(cited 1998) (1998).
3. Finn, O. J. & Forni, G. Prophylactic cancer vaccines. Curr. Opin. Immunol. 14, 172-177 (2002).
4. Berinstein, N. Overview of theraputic vaccination approaches for cancer. Semin. Oncol. 30, 1-8 (2003).
5. Jager, E., Jager, D., & Knuth, A. Clinical cancer vaccine trials. Curr. Opin. Immunol. 14, 178-182 (2002).
6. Zinkernagel, R. M. On natural and artifical vaccinations. Annu. Rev. Immunol. 21, 515-546 (2003).
7. Walsh, G. Biopharmaceutical benchmarks - 2003. Nature Biotechnol. 21, 865-870 (2003).
8. Dalum, I. et al. Therapeutic antibodies elicited by immunization against TNF-α. Nature Biotechnol. 17, 666-669 (1999).
9. Gardiner, S. M. et al. Active immunization with angiotensin I peptide analogue vaccines selectively reduces the pressor effects of exogenous angiotensin I in conscious rats. Br. J. Pharmacol. 129, 1178-1182 (2000).
10. Richard, M., Grencis, R. K., Humphreys, N. E., Renaultd, J. C. & Van Snick, J. Anti-IL -9 vaccination prevents worm expulsion and blood eosinophillia in Trichuris muris-infected mice. Proc. Natl Acad. Sci. USA 97, 767-772 (2000),
11. Hertz, M. et al. Active vaccination against IL-5 bypasses immunological tolerance and ameliorates experimental asthma. J. Immunol. 167, 3792-3799 (2001).
12. During, M. J. et al. An oral vaccine against NMDAR1 with efficacy in experimental stroke and epilepsy. Science 287, 1453-1460 (2000).
13. Talwar, G. P. et al. A vaccine that prevents pregnancy in women. Poc. NAtl Acad. Sci. USA 91, 8532-8536 (1994).
14. Simms, M. S. et al. Anti-GnRH antibodies can induce castrate levels of testosterone in patients with advanced prostate cancer. Br. J. Cancer 83, 443-446 (2000).
15. Brett, B. T. et al. Phase II study of anti-gastrin-17 antibodies, raised to G17DT, in advanced pancreatic cancer. J. Clin. Oncol. 20, 4225-4231 (2002).
16. Schenk, D. et al. Immunization with amyloid-β attenuates Alzhimer-disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
17. Morgan, D. et al. A β-peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408,982-985 (2000).
18. Orgogozo, J. M. et al. Subacute meningoencephalitis in a subset of patients with AD after Aβ42 immunization. Neurology 61, 46-54 (2003).
19. Hock, C. et al. Generation of antibodies specific for β-amyloid by vaccination of patients with Alzheimer disease. Nature Med. 8, 1270-1275 (2002).
20. Hock, C. et al. Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron 38, 547-554 (2003)
21. Nicoll, J. A. et al. Neuropathology of human Alzheimer disease after immunization with amyloi-β peptide: a case report. Nature Med. 9, 448-452 (2003).
22. Fox, B. S. et al. Efficacy of a therapeutic cocaine vaccine in rodent models. Nature Med. 2, 1129-1132 (1996).
23. Lindblom, N. et al. Active immunization against nicotine prevents reinstatment of nicotine-seeking behavior in rats. Respiration 69, 254-260 (2002).
24. Kosten, T. R. et al. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 20, 1196-1204 (2002).
25. Dinarello, C. A. Anti-cytokine therapeutics and infections. Vaccine 21 (Suppl. 2), S24-S34 (2003).
26. Van den Brande, J. M. et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 124, 1774-1785 (2003).
27. Tew, J. G., Phipps, R. P. & Mandel, T. E. The maintenance and regulation of the humoral immune response: persisting antigen and the role of follicular antigen-binding dendritic cells as accessory cells. Immunol. Rev. 53, 175-201 (1980).
28. Bachmann, M. F., Kundig, T. M., Hengartner, H. & Zinkernagel, R. M. Regulation of IgG antibody titers by the amoung persisting of immune-complexed antigen. Eur. J. Immunol. 24, 2567-2570 (1994).
29. McHeyzer-Williams, M. G. & Ahmed, R. B cell memory and the long-lived plasma cell. Curr. Opin. Immunol. 11 172-179 (1999).
30. Manz, R. A. et al. Humoral immunity and long-lived plasma cells. Curr. Opin. Immunol. 14, 517-521 (2002).
31. Bernasconi, N. L., Traggiai, E. & Lanzavecchia, A. Maintenance of serological memory by polyclonal activation of human memory B cells. Science 298, 2199-2202 (2002).
32. Sebzda, E. et al. Selection of the T cell repertoire. Annu. Rev. Immunol. 17, 829-874 (1999).
33. Bachmann, M. F. & Kopf, M. Balancing protective immunity and immunopathology. Curr. Opin. Immunol. 14, 413-419 (2002).
34. O'Hagan, D. T. & Valiante, N. M. Recent advances in the discovery and delivery of vaccine adjuvants. Nature Rev. Drug Discov. 2, 727-735 (2003).
35. Janeway, C. A. Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol. 54, 1-13 (1989).
36. Behboudi, S., Morein, B. & Villacres-Eriksson, M. In vitro activation of antigen-presenting cells (APC) by defined composition of Quillaja sapnonaria MOlina triterpenois. Clin. Exp. Immunol. 105, 26-30 (1996).
37. Chung, H., Brazil, M.I., Soe, T. T. & Maxfield, F. R. Uptake, degradation, and release of fibrillar and soluble forms of Alzheimer's amyloid β-peptide by microglial cells. J. Biol. Chem. 274, 32301-32308 (1999).
38. Gotz, J., Chen, F., van Dorpe, J.& Nitsch, R. M. Formation of neurofibrillary tangles in P301I tau transgenic mic induced by Aβ 42 fibrils. Science293, 1491-1495 (2001).
39. Rammensee, H., Bachmann, J., Emmerich, N. P., Bachor, O. A. & Stevanovic, S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics 50, 213-219 (1999).
40. Bachmann, M. F. & Zinkernagel, R.M. Neutralizing antiviral B cell responses. Annu. Rev. Immunol. 15, 235-270 (1997).
41. Weigle, W. O. Analysis of autoimmunity through experimental models of thyroiditis and allergic encephalomyelitis. Adv. Immunol. 30, 159-273 (1980).
42. Goodnow, C. C. B-cell tolerance. Curr. Opin. Immunol. 4,703-710 (1992).
43. Nemazee, D. et al. Clonal deletion of autospecific B lymphocytes. Immunol. Rev. 122, 117-132 (1991).
44. Bachman, M. F. et al. The influence of antigen organization on B cell responsiveness. Science 262, 1448-1451 (1993).
45. Chackerian, B., Lowy, D. R. & Schiller, J. T. Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J. Clin. Invest. 108, 415-423 (2001).
46. Jegerlehner, A. et al. A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 20, 3104-3112 (2002).
47. Storni, T. et al. Criticial role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol. 168,2880-2286 (2002).
48. Storni, T., Ruedl, C., Renner, W. A. & Bachmann, M. F. Innate immunity together with duration of antigen persistence regulate effector T cell induction. J. Immunol. 171, 795-801 (2003).
49. Frantz, S. & Smith, A. New drug approvals for 2002. Nature Rev. Drug Discov. 2, 95-96 (2003).
50. Dyer, M. R. & Herrling, P. L. Progress and potential for gene-based medicines. Mol. Ther. 1, 213-224 (2000).
51. Fletcher, L. Roche leads molecular diagnostics charge. Nature Biotechnol. 20, 6-7 (2002).
52. WHO. Integrating prevention into health care [online], (cited2002) (2002).
53. WHO. Tobacco - Health Facts [online], (cited 1999) (1999).
54. Burnier, M., Santschi, V., Favrat, B. & Brunner, H. R. Monitoring compliance in resistant hypertension: an important step in patient management. J. Hypertens. Suppl. 21 (Suppl. 2), S37-S42 (2003).
55. Miller, N. H. Compliance with treatment regimens in chroni asymptomatic diseases. Am. J. Med. 102 43-49 (1997).
56. German, P. S. Compliance and chronic disease. Hypertension 11, II56-II60 (1988)
57. Spohn, G. & Bachmann, M. F. Therapeutic vaccination to block receptor-ligand interactions. Expert Opin. Biol. Ther. 3, 469-476 (2003).